Tumour tissue transport after intraperitoneal anticancer drug delivery |
| |
| Authors: | Charlotte Carlier Ada Mathys Emiel De Jaeghere Margo Steuperaert Olivier De Wever |
| |
| Affiliation: | 1. Laboratory for Experimental Surgery, Department of Surgery, Ghent University, Ghent, Belgium;2. Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium;3. Biofluid, Tissue and Solid Mechanics for Medical Applications (bioMMeda), Department of Electronics and Information Systems, iMinds Medical IT Department, Ghent University, Ghent, Belgium;4. Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium |
| |
| Abstract: | AbstractIntraperitoneal (IP) drug delivery, either as an intraoperative chemoperfusion or as an adjuvant, repeated instillation, is an established treatment modality in patients with peritoneal carcinomatosis. The efficacy of IP drugs depends on its ability to penetrate the tumour stroma in order to reach their (sub)cellular target. It is known, that drug penetration after IP delivery is limited to a few millimetres. Here, we review the basic tissue transport mechanisms after IP delivery and discuss the biophysical barriers and obstacles that limit penetration distance. In addition, we review the physical and pharmaceutical interventions that have been studied in order to improve delivery of small molecular and macromolecular drugs after IP instillation. These interventions could inform the design of future clinical trials aiming at an improved efficacy of IP-based drug delivery in carcinomatosis patients. |
| |
| Keywords: | Intraperitoneal carcinomatosis drug delivery pharmacokinetics |
|
|
